nbsp; 长方形、蓝色、薄膜包衣片剂 单面印有“M50” 71334-215-50
PYRUKYND锥形包装
片剂剂量 Blister钱 片剂说明 印记 NDC
包配置
5毫克 5毫克泡罩 圆形蓝色薄 单面印有“M5” 71334-220-11
钱包，含7片 膜包衣片剂
20毫克和 20毫克泡罩钱 圆形、蓝色、 单面印有“M20” 71334-225-12
5毫克 包，含7片 薄膜包衣片剂 单面印有“M5”
5毫克泡罩钱
包，含7片
50毫克和 50毫克泡罩钱 长方形蓝色薄 单面印有“M50” 71334-230-13
20毫克 包，含7片 膜包衣片剂 单面印有“M20”
20毫克泡罩钱 圆形蓝色薄膜
包，含7片 包衣片剂
存储
在20°C至25°C（68°F至77°F）下储存，允许在15°C至30°C（59°F至86°F）之间进行短途旅行[见USP受控室温]。将泡罩钱包存放在原始纸箱中，直到使用。
请参阅随附的PYRUKYND完整处方信息：
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ccee896-e313-4c6c-9674-b4746ada0a90
-------------------------------------------
The US FDA has approved its new drug Pyrukynd for the treatment of hemolytic anemia in adults with pyruvate kinase (Pyruvate Kinase, PK)deficiency. Pyrukynd is a first-in-class oral PK activator and the first approved corrective therapy for this disease.
PRINCIPAL DISPLAY PANEL - 5 MG TABLET BLISTER PACK CARTON
NDC 71334-205-05
Do not use if seal
is broken or damaged
Rx Only
pyrukynd ®
(mitapivat) tablets
5 mg per tablet
56 tablets
Contains 4-week supply of PYRUKYND ®
(Four 7-day blister wallets with 14 tablets per wallet)
Swallow tablets whole. Do Not split, crush, chew, or dissolve the tablets.
PRINCIPAL DISPLAY PANEL - 20MG TABLET BLISTER PACK CARTON
NDC 71334-210-20
Do not use if seal
is broken or damaged
Rx Only
pyrukynd ®
(mitapivat) tablets
20 mg per tablet
56 tablets
Contains 4-week supply of PYRUKYND ®
(Four 7-day blister wallets with 14 tablets per wallet)
Swallow tablets whole. Do Not split, crush, chew, or dissolve the tablets.
PRINCIPAL DISPLAY PANEL - 50 MG TABLET BLISTER PACK CARTON
NDC 71334-215-50
Do not use if seal
is broken or damaged
Rx Only
pyrukynd ®
(mitapivat) tablets
50 mg per tablet
56 tablets
Contains 4-week supply of PYRUKYND ®
(Four 7-day blister wallets with 14 tablets per wallet)
Swallow tablets whole. Do Not split, crush, chew, or dissolve the tablets.
50 mg Blister Carton
CLOSE
PRINCIPAL DISPLAY PANEL - 5 MG TABLET BLISTER PACK CARTON - 220-11
NDC 71334-220-11
Do not use if seal is broken or damaged
Rx Only
pyrukynd ®
( |
